Prostanoids

Bioactive Lipids

Volumn , Issue , 2012, Pages 197-222

  Nicolaou, Anna ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942751054     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9780857097934.197     Document Type: Chapter

References (85)

1. Balsinde J., Balboa M.A., Dennis E.A. Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc Natl Acad Sci USA 1998, 95:7951-7956.
2. Balsinde J., Winstead M.V., Dennis E.A. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett 2002, 531:2-6.
3. Bao Y., Pucci M.L., Chan B.S., Lu R., Ito S., Schuster V.L. Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am J Physiol Renal Physiol 2002, 282:F1103-F1110.
4. Baranowski R., Pacha K. Gas chromatographic determination of prostaglandins. Mini Rev Med Chem 2002, 2:135-144.
5. Battistini B., Picard S., Borgeat P., Sirois P. Measurements of prostanoids, leukotrienes, and isoprostanes by enzyme immunoassays. Methods Mol Biol 1998, 105:201-207.
6. Bazan N.G., Colangelo V., Lukiw W.J. Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat 2002, 69:197-210.
7. Bishop-Bailey D., Calatayud S., Warner T.D., Hla T., Mitchell J.A. Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol 2002, 21:93-101.
8. Boie Y., Sawyer N., Slipetz D.M., Metters K.M., Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995, 270:18910-18916.
9. Breyer M.D., Breyer R.M. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 2001, 63:579-605.
10. Breyer R.M., Bagdassarian C.K., Myers S.A., Breyer M.D. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001, 41:661-690.
11. Calder P.C. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 2001, 36:1007-1024.
12. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., Simmons D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002, 99:13926-13931.
13. Christie W.W. Preparation of lipid extracts from tissues. Advances in Lipid Methodology 2 1993, 195-213. The Oily Press, Bridgwater. W.W. Christie (Ed.).
14. Davidge S.T. Prostaglandin H synthase and vascular function. Circ Res 2001, 89:650-660.
15. Dennis E.A. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci 1997, 22:1-2.
16. Engblom D., Saha S., Engstrom L., Westman M., Audoly L.P., Jakobsson P.J., Blomqvist A. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nature Neurosci 2003, 6:1137-1138.
17. Fink A.N., Frishman W.H., Azizad M., Agarwal Y. Use of prostacyclin and its analogues in the treatment of cardiovascular disease. Heart Dis 1999, 1:29-40.
18. FitzGerald G.A. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002, 89:26D-32D.
19. FitzGerald G.A. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nature Rev Drug Discov 2003, 2:879-890.
20. Forsberg L., Leeb L., Thoren S., Morgenstern R., Jakobsson P. Human glutathione dependent prostaglandin E synthase: gene structure and regulation. FEBS Lett 2000, 471:78-82.
21. Fuentes L., Hernandez M., Nieto M.L., Sanchez Crespo M. Biological effects of group IIA secreted phosholipase A(2). FEBS Lett 2002, 531:7-11.
22. Galie N., Manes A., Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 2001, 22:529-537.
23. Gasparini G., Longo R., Sarmiento R., Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol 2003, 4:605-615.
24. Gessler T., Schmehl T., Olschewski H., Grimminger F., Seeger W. Aerosolized vasodilators in pulmonary hypertension. J Aerosol Med 2002, 15:117-122.
25. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nature Med 1999, 5:698-701.
26. Goodwin D.C., Landino L.M., Marnett L.J. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J 1999, 13:1121-1136.
27. Hansen W.R., Keelan J.A., Skinner S.J., Mitchell M.D. Key enzymes of prostaglandin biosynthesis and metabolism. Coordinate regulation of expression by cytokines in gestational tissues: a review. Prostaglandins Other Lipid Mediat 1999, 57:243-257.
28. Hardy P., Dumont I., Bhattacharya M., Hou X., Lachapelle P., Varma D.R., Chemtob S. Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc Res 2000, 47:489-509.
29. Harris R.C. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002, 89:10D-17D.
30. Hirabayashi T., Shimizu T. Localization and regulation of cytosolic phospholipase A(2). Biochim Biophys Acta 2000, 1488:124-138.
31. Hong K.H., Bonventre J.C., O'Leary E., Bonventre J.V., Lander E.S. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc Natl Acad Sci USA 2001, 98:3935-3939.
32. Houchen C.W., Stenson W.F., Cohn S.M. Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury. Am J Physiol Gastrointest Liver Physiol 2000, 279:G858-G865.
33. Ide T., Egan K., Bell-Parikh L.C., FitzGerald G.A. Activation of nuclear receptors by prostaglandins. Thromb Res 2003, 110:311-315.
34. Ito S., Okuda-Ashitaka E., Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001, 41:299-332.
35. Jakobsson P.J., Thoren S., Morgenstern R., Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999, 96:7220-7225.
36. Kudo I., Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 2002, 69:3-58.
37. Lim H., Dey S.K. A novel pathway of prostacyclin signaling - hanging out with nuclear receptors. Endocrinology 2002, 143:3207-3210.
38. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999, 96:272-277.
39. Melian E.B., Goa K.L. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002, 62:107-133.
40. Miyata A., Yokoyama C., Ihara H., Bandoh S., Takeda O., Takahashi E., Tanabe T. Characterization of the human gene (TBXAS1) encoding thromboxane synthase. Eur J Biochem 1994, 224:273-279.
41. Monjazeb A.M., Clay C.E., High K.P., Chilton F.H. Antineoplastic properties of arachidonic acid and its metabolites. Prostaglandins Leukot Essent Fatty Acids 2002, 66:5-12.
42. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002, 63:817-821.
43. Murakami M., Naraba H., Tanioka T., Semmyo N., Nakatani Y., Kojima F., Ikeda T., Fueki M., Ueno A., Oh S., Kudo I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000, 275:32783-32792.
44. Murakami M., Nakatani Y., Tanioka T., Kudo I. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 2002, 69:383-399.
45. Narumiya S., FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001, 108:25-30.
46. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999, 79:1193-1226.
47. Parente L., Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003, 65:153-159.
48. Patrono C., Patrignani P., Garcia Rodriguez L.A. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical readouts. J Clin Invest 2001, 108:7-13.
49. Reid G., Wielinga P., Zelcer N., van der Heijden I., Kuil A., de Haas M., Wijnholds J., Borst P. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 2003, 100:9244-9249.
50. Ross J.A., Fearon K.C. Eicosanoid-dependent cancer cachexia and wasting. Curr Opin Clin Nutr Metab Care 2002, 5:241-248.
51. Sapirstein A., Bonventre J.V. Specific physiological roles of cytosolic phospholipase A(2) as defined by gene knockouts. Biochim Biophys Acta 2000, 1488:139-148.
52. Schuster V.L. Prostaglandin transport. Prostaglandins Other Lipid Mediat 2002, 69:633-647.
53. Schwab J.M., Schluesener H.J., Meyermann R., Serhan C.N. COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics?. Prostaglandins Leukot Essent Fatty Acids 2003, 69:339-343.
54. Serhan C.N., Levy B. Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics. Proc Natl Acad Sci USA 2003, 100:8609-8611.
55. Serhan C.N., Oliw E. Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest 2001, 107:1481-1489.
56. Shimizu T. The future potential of eicosanoids and their inhibitors in paediatric practice. Drugs 1998, 56:169-176.
57. Six D.A., Dennis E.A. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 2000, 1488:1-19.
58. Slater D.M., Zervou S., Thornton S. Prostaglandins and prostanoid receptors in human pregnancy and parturition. J Soc Gynecol Investig 2002, 9:118-124.
59. Slater T.F., McDonald-Gibson R.G. Introduction to the eicosanoids. Prostaglandins and Related Substances: A Practical Approach 1987, 1-4. IRL Press, Oxford. C. Benedetto, R.G. McDonanld-Gibson, S. Nigam, T.F. Slater (Eds.).
60. Smith K.J., Skelton H. Arachidonic acid-derived bioactive lipids: their role and the role for their inhibitors in dermatology. J Cutan Med Surg 2002, 6:241-256.
61. Smith W.L., Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001, 107:1491-1495.
62. Smith W.L., Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat 2002, 69:115-128.
63. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
64. Straus D.S., Glass C.K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001, 21:185-210.
65. Sugimoto Y., Narumiya S., Ichikawa A. Distribution and function of prostanoid receptors: studies from knockout mice. Prog Lipid Res 2000, 39:289-314.
66. Susanna R., Chew P., Kitazawa Y. Current status of prostaglandin therapy: latanoprost and unoprostone. Surv Ophthalmol 2002, 47:S97-S104.
67. Suzuki-Yamamoto T., Nishizawa M., Fukui M., Okuda-Ashitaka E., Nakajima T., Ito S., Watanabe K. cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett 1999, 462:335-340.
68. Svensson C.I., Yaksh T.L. The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 2002, 42:553-583.
69. Tai H.H., Ensor C.M., Tong M., Zhou H., Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 2002, 69:483-493.
70. Tapiero H., Ba G.N., Couvreur P., Tew K.D. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother 2002, 56:215-222.
71. Tilley S.L., Coffman T.M., Koller B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001, 108:15-23.
72. Ueno N., Murakami M., Tanioka T., Fujimori K., Tanabe T., Urade Y., Kudo I. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J Biol Chem 2001, 276:34918-34927.
73. Ullrich V., Zou M.H., Bachschmid M. New physiological and pathophysiological aspects on the thromboxane A(2)-prostacyclin regulatory system. Biochim Biophys Acta 2001, 31:1-2.
74. Uozumi N., Shimizu T. Roles for cytosolic phospholipase A2alpha as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediat 2002, 69:59-69.
75. Urade Y., Eguchi N. Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins Other Lipid Mediat 2002, 69:375-382.
76. 2 and sleep regulation. Biochim Biophys Acta 1999, 4(3):606-615.
77. Urquhart P., Parkin S.M., Rogers J.S., Bosley J.A., Nicolaou A. The effect of conjugated linoleic acid on arachidonic acid metabolism and eicosanoid production in human saphenous vein endothelial cells. Biochim Biophys Acta 2002, 28:2-3.
78. Vane J.R., Botting R.M. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998, 47:S78-S87.
79. Warner T.D., Mitchell J.A. Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: as easy as ABC?. Proc Natl Acad Sci USA 2003, 100:9108-9110.
80. Watanabe K. Prostaglandin F synthase. Prostaglandins Other Lipid Mediat 2002, 69:401-407.
81. Winstead M.V., Balsinde J., Dennis E.A. Calcium-independent phospholipase A(2): structure and function. Biochim Biophys Acta 2000, 1488:28-39.
82. Wise H., Wong Y.H., Jones R.L. Prostanoid signal integration and cross talk. Neurosignals 2002, 11:20-28.
83. Yang P., Felix E., Madden T., Fischer S.M., Newman R.A. Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells. Anal Biochem 2002, 308:168-177.
84. Yedgar S., Lichtenberg D., Schnitzer E. Inhibition of phospholipase A(2) as a therapeutic target. Biochim Biophys Acta 2000, 1488:182-187.
85. Zimmermann K.C., Sarbia M., Schror K., Weber A.A. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998, 54:536-540.